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INTRODUCTION 
Acute viral bronchiolitis is one of the most common causes 
of lower respiratory tract infection during infancy and also 
the most common cause of hospital admission among 
infants and young children in many countries. 
Bronchiolitis is most common in the first 2 years of life.1,2 
Usually, the child first experiences colds, such as cough, 
runny nose, and after two or three days, a sudden onset of 
breathing, wheezing, swollen and superficial breathing (up 
to 60 times per minute), interstitial spaces and abdomen 
(Swirling movements), coughing, fever, wheeze and 
crackle in the lungs, nasal sprains, the use of subcutaneous 
muscles and increased heart rate, decreased oxygen 
saturation.3 
For disease diagnosis, laboratory and radiologic check is 
not usually needed. Diagnosis of bronchiolitis is a clinical 
diagnosis and is done based on patient history, physical 
examination and exclusion of other causes of respiratory 
distress. For bronchiolitis no short-term or long-term 
treatment has ever been confirmed and the treatment is still 
supportive and oxygen prescription, fluid and suction 
secretions from the upper airway and mechanical 
ventilation if necessary. In cases where the pathogen is a 
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virus, antibiotic treatment is not necessary and only the 
symptoms such as fever and wheezing are treated.4-7  
Currently the inhalation of HS as a treatment option has 
been proposed and the conducted limited studies in this 
area have shown that the use of HS has been useful in 
improving severity scores and the reduction of LOS.7-13 
Adrenaline inhalation as a common routine treatment used 
for bronchiolitis, in addition to expanding the bronchi, may 
reduce mucosal edema. Considering the limited number of 
studies and the lack of similar trials in this country Iran, 
this study was aimed to investigate the effect of nebulized 
5% and 7% Hypertonic Saline (HS) versus Normal Saline 
(NS) in acute viral bronchiolitis. 
METHODS 
Authors conducted a prospective, randomized controlled 
trial in 90 infants presenting with acute bronchiolitis.  
Patient selection  
Informed consent was obtained from a parent or legal 
guardian of each infant enrolled in the study. Patients age 
8 weeks to ≤24 months admitted to the children hospital 
between April 2016 to Sep 2016 with bronchiolitis 
(defined as first episode of respiratory distress with 
wheezing and viral) and a bronchiolitis severity score 
(BSS) more than 4 were eligible for the study (Table 1).14 
Table 1: Assessment of bronchiolitis severity in infants based on RDAI scale. 
Score symptoms  0 1 2 3 
Wheezing 
While exhaling None Exhale end Half an Exhale Three quarters of an exhale 
While respire None Incomplete Complete - 
Number of lobes involved in the 
lung 
0 1 or 2 3 or 4 - 
Retraction 
Supraclavicular None Mild Moderate Severe 
Between the ribs None Mild Moderate Severe 
below the rib cage None Mild Moderate Severe 
Inclusion criteria included age ≤24 months, diagnosis of 
bronchiolitis by pediatrician by clinical examination of 
wheezing and viral detection and CXR. We excluded 
infants who had pulmonary and heart disease, Down 
syndrome, immune deficiency, metabolic disease, inhaled 
brunch dilator uses or previous episodes of wheezing.  
Study protocol  
All eligible patients were randomized to 1 of 3 groups. The 
study groups received 0.15 mg/kg Adrenaline with 4 ml 
nebulized 5% and 7% HS, respectively and the control 
group received 0.15 mg/kg Adrenaline with 4 ml 0.9% NS 
every 6 hours from enrolment until hospital discharge.  
LOS and recovery time of clinical symptoms such as 
cough, wheezing and sputum and other symptoms for all 
groups were recorded in following days (end of study) 
objectively by clinical examination by pediatrician. Also, 
infants were systematically monitored for adverse events 
during the hospitalization and followed with a phone call 
by research personnel two weeks after hospital discharge. 
Statistical analysis 
Authors compared patient demographic and clinical 
characteristics between groups by using chi-square test for 
categorical variables and t-test and ANOVA for compare 
the means between two and three groups. The significant 
level was set as p<0.05.  
This study was approved in ethics committee of Ardabil 
University of medical sciences with number of 
arums.rec.1394.19 and registered in Iran clinical trials web 
pages with code IRCT2015090717843N5.  
RESULTS 
The mean age of the total patients was 5.5 ±3.6 months and 
most of them were in the age group of 2 to 6 month 
(58.9%). Of all patients, 59 (65.6%) were male and 19 
(2.1%) had taken antibiotics before admission to study. All 
three groups are similar in-Patient characteristics and 
clinical symptoms in the admission to study (Tables 2 and 
Table 3). 
Table 2: Characterized of patients in the start of study 
before intervention. 
Groups  
Variables  
0.9% 
Normal 
saline, 
n=30 
5% HS, 
n=30 
7% HS, 
n=30 
p-
value  
Age, mo, 
mean±SD 
5.7±4.8 5.5±3 5.2±2.6 0.88 
Gender, 
male 
20/30 
(33.9%) 
22/30 
(37.3%) 
17/30 
(28.8%) 
0.39 
Duration of 
symptoms, 
mean±SD 
2.13±1 1.7±0.7 1.8±0.7 0.096 
Antibiotic 
use 
9/30 
(47.4%) 
6/30 
(31.6%) 
4/30 
(21.1%) 
0.28 
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Table 3: Frequency of clinical symptoms in patients in 
baseline by three groups. 
Symptoms  
0.9% 
Normal 
Saline, 
n=30 
5% 
HS, 
n=30 
7% HS, 
n=30 
p-
value  
Sputum 
5 /30 
(16.7%) 
7/30 
(23.3%) 
4/30 
(13.3%) 
0.58 
Wheezing 
30 /30 
(100%) 
30/30 
(100%) 
30/30 
(100%) 
1 
Crackle 
25/30 
(83.3%) 
27/30 
(90%) 
27/30 
(90%) 
0.78 
Retraction 
9/30 
(30%) 
15/30 
(50%) 
13/30 
(43.3%) 
0.28 
Increased 
breathing 
23/30 
(76.7%) 
24/30 
(80%) 
27/30 
(90%) 
0.37 
Fever 
11/30 
(36.7%) 
17/30 
(56.7%) 
12/30 
(40%) 
0.25 
Irritability 
4/30 
(13.3%) 
5/30 
(16.7%) 
5/30 
(16.7%) 
1 
Week 
nutrition 
21/30 
(70%) 
14/30 
(46.7%) 
16/30 
(53.3%) 
0.17 
Increased 
hearth rate 
3/30 
(10%) 
4/30 
(13.3%) 
6/30 
(20%) 
0.65 
There was significant difference in the mean length of 
cough, Crackle and LOS between three groups. But there 
wasn’t significant difference between three groups in 
terms of Wheezing, fever, and sputum (Table 4). 
Table 4: Compare the clinical symptoms in three 
groups in the end of study. 
Symptoms 
0.9% 
Normal 
Saline, 
n=30 
5% HS, 
n=30 
7% HS, 
n=30 
p-
value 
Length of 
wheezing 
(day) 
3.4±1.1 3.03±1.13 2.97±0.9 0.23 
Duration of 
cough (day) 
3.1±1.4 2.3±1.6 2.33±1.12 0.044 
Length of 
Crackle(day) 
1.63±1.2 0.87±0.9 0.8±1 0.003 
Length of 
stay (LOS) 
(day) 
4.13±1.1 3.37±1.1 3.23±0.9 0.002 
Length of 
fever (day) 
0.33±0.5 0.5±0.51 0.4±0.49 0.427 
Length of 
sputum 
(day) 
0.4±1 0.1±0.4 0.23±0.8 0.307 
The mean of LOS in two interventional groups within age 
groups of 2 to 6 months (P=0.003) and 6 to 12 months 
(P=0.004) was significantly lower than control group. 
In the age group 2 to 6 months, the mean length of crackle 
in patients receiving hypertonic saline 5% and 7% was 
significantly lower than control group. But another 
symptoms such as length of wheezing, cough, fever, 
sputum, need for oxygen therapy in two age groups 2 to 6 
months and 6-12 months was similar between three 
groups. 
DISCUSSION 
In this study we showed that infants receiving 7% HS 
(P=0.004) and 5% HS (P=0.016) considerably recovered 
and discharged in a shorter period of time compared to 
infants receiving NS, but among two nebulized 7% HS and 
5% HS there was no difference in this regard. 
Most of previous studies showed that 3% HS is better than 
NS in the treatment of viral bronchiolitis in children which 
was in line with our study results but some studies showed 
it is not better than 0.9% NS.8-19 
Many studies showed that 5% HS in treatment of 
bronchiolitis in children is better than 0.9% NS.8,20,21 
Jacobs et al, conducted a clinical trial and showed that use 
of 7% HS with epinephrine did not have a considerable 
effect on the severity and LOS of the infants under 18 
months with viral bronchiolitis which not in line with our 
study results.22 All children in this study well tolerated the 
treatment and it was predictable because previous studies 
had shown that 7% and 5% HS are well tolerated by 
patients.23,24 
Also in a study conducted by Goss and Ratjn, it was shown 
that 7% HS use in the treatment of cystic fibrosis in 
children under 6 years old is perfectly safe.22 Regarding 
the safety of 5% HS, the study of Tinsa et al, showed that 
using it even without bronchodilator in infants under 12 
months is well tolerated and had no significant 
complication.20 
Like many similar studies, in this study, along with 7% HS, 
5% HS, and NS, 0.15mg/kg adrenaline was used in all 
three groups.8,10,19,20,24-28 Hypertonic saline was shown to 
be more effective than NS in improving bronchiolitis 
clinical scores in 5 studies in both outpatient and inpatient 
settings.29-33 
Five studies noted that LOS for patients who received 
hypertonic saline was shorter than for those given NS, 
which is consistent with the results of our study.11,12,31-33 
One of the findings of the present study was the 
considerable reduction in LOS in both two 7% HS and 5% 
HS receiving groups compared to NS control group which 
in addition to its clinical importance, can cause a 
significant reduction in the cost of patients treatments. In 
line with the findings of our study, in the studies of Zamani 
et al, and Mandlberg et al, recovery duration of 3% HS 
group was significantly lower than patients with NS.9,16 On 
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the contrary, the study of Tinsa et al, did not show any 
significant difference in LOS between two groups of 5% 
HS and NS.20 In the study of Jacobs et al, there was no 
difference in LOS of infants with bronchiolitis receiving 
7% HS with NS.24 Our study did not reveal a difference 
between 7% and 5% HS in terms of cough length, crackles 
length or LOS but in compared with NS the difference was 
significant. 
CONCLUSION 
This study showed that using 5% and 7% HS in compare 
with NS have significant effect on the Reducing the 
recovery time, discharge from the hospital and also 
duration of coughing and crackle in 2-24 month infants 
with viral bronchiolitis. Also authors found that using each 
of 5% HS or 7% HS was similar affect in treatment of viral 
bronchiolitis and hadn’t any significant side-effects in 
infants and well tolerated by them. Authors recommended 
that doing multi-center studies with bigger sample size and 
more systematic review studies for better response to 
arisen contradictions of this study with other studies in 
future is necessary. 
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